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Abstract 
 
Vascular calcification strongly correlates with declining renal function and contributes to 
the high morbidity and mortality of patients with chronic kidney disease (CKD). It is 
closely regulated by circulating factors but little is known about the potential of serum 
from patients to induce calcification outside the disease setting – the calcific potential of 
serum. We have therefore examined the ability of serum from age- and sex-matched 
subjects with and without advancing CKD to induce calcification of cultured smooth 
muscle cells. Samples from patients with CKD induced significant calcification 
compared with controls. More importantly, samples from patients on haemodialysis 
induced significantly higher calcification than those with moderate or advanced CKD. 
The calcification induced by the latter two but not those on haemodialysis could be 
enhanced with calcium chloride and β-glycerophosphate. A positive correlation was 
evident between measured serum creatinine, phosphate, parathyroid hormone, 
osteoprotegerin and the degree of calcification in vitro. Estimated glomerular filtration 
rate, diastolic blood pressure, haemoglobin and serum albumin correlated negatively. 
Stepwise multivariate analysis of log-transformed calcific potential data highlighted 
serum creatinine, albumin and osteoprotegerin as significant predictors, explaining 
around 50% of the variation. Thus, other regulators either not investigated or as yet 
unidentified, may contribute to  the calcification potential of serum in vitro. Furthermore, 
uremic serum can induce graded calcification outside of the disease milieu that reflects 
the degree of kidney impairment in vivo. These findings could have important clinical 
relevance in terms of developing novel diagnostic and/or therapeutic strategies for 
subjects with CKD. 
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INTRODUCTION 
 
Calcification is a common occurrence in end-stage renal failure and shows a strong 
correlation with declining renal function [1]. It often results in a diverse range of 
pathologies including calcific uraemic arteriolopathy, solid as well as extra-osseous soft 
tissue calcification of which vascular calcification (VC) is the most common and often 
the most clinically relevant corollary. The existence of VC in chronic kidney disease 
(CKD) results in increased arterial stiffness, becoming predictive of secondary 
cardiovascular complications with high morbidity and mortality [2, 3].  
 
The precise mechanisms that lead to VC in CKD subjects are poorly understood but it is 
accepted to be a delicate and well-controlled biological process that results in smooth 
muscle cells (SMCs) gaining an osteoblastic phenotype [4]. These complex changes 
may be regulated in vivo by circulating factors in plasma and, interestingly, in vitro by 
uremic serum especially under hyperphosphatemic conditions [5]. The latter 
demonstrates that serum from pathological settings may have a potential to induce VC 
even outside the disease milieu and provides a means through which the mechanisms 
associated with this process can be investigated. More importantly, the ability of serum 
to induce calcification in vitro could be exploited to predict the risk of calcification in vivo 
during routine tests, and applied to the clinical management of patients. To achieve this, 
a robust biological model is required in which the calcific potential of individual serum 
samples can be validated, and trends within defined groups of CKD patients identified to 
allow the establishment of threshold scores which might guide the need for intervention.  
 
We have developed an in vitro model of calcification in smooth muscle cells and 
embarked on a program of studies to establish the calcific potential (i.e. ability to induce 
calcification) of individual serum samples from cohorts of patients with CKD. More 
specifically, we have investigated whether serum from patients with stages 3, 4/5 CKD 
or on haemodialysis (5D) has a greater in vitro calcific potential than normal age- and 
sex-matched controls. We also wished to establish whether in vitro calcific potential 
correlated with the degree of renal impairment. In parallel, we have characterised each 
patient in terms of disease vintage, extra-renal co-morbidity, and smoking history. 
Furthermore, we have related the calcific potential of serum in individuals to the levels 
of biochemical markers and report for the first time that CKD serum induces graded 
calcification outside of the disease milieu that correlates with the degree of kidney 
impairment, and with specific biomarkers which may, in part, explain the potential of 
serum to induce calcification in vitro.  
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METHODS  
 
Ethical approval 
 
Ethical approval was obtained from the Hertfordshire Research Ethics Committee. The 
procedures followed were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2000. The study subjects gave written informed 
consent prior to recruitment into the study.  
 
Patient recruitment 
 
All the patients were recruited from the renal clinics in East and North Herts NHS Trust 
hospitals in Hertfordshire, UK. Inclusion criteria for the patients with CKD were age >18 
years, glomerular filtration rate (eGFR) by MDRD-4 formula less than 60 ml/min. 
Exclusion criteria were immunosuppressive therapy, pregnancy, hormone replacement 
therapy and malignancy. Twenty age- and sex-matched healthy individuals with normal 
renal function, without diabetes or in vivo calcification as detected with CT scan were 
recruited as controls. There were 70 subjects in the patient group who, based on eGFR, 
were classified into a moderate (stage 3 CKD; 21 subjects), advanced (stage 4 and 5 
CKD; 18 subjects) or haemodialysis group (5D; 30 subjects). In the 5D group only those 
patients who had undergone at least 3 months of dialysis were considered. 
 
Data collection 
 
Demographic and clinical variables including age, gender, and blood pressure were 
recorded. Blood samples in controls and pre-dialysis patients were collected during 
routine visits and those of haemodialysis patients were collected immediately before 
dialysis sessions. Samples were taken into Z serum sep clot activator VACUTTE®, 
centrifuged at 2500 rpm for 15 minutes at 4oC and the serum stored at -80oC until 
analysed.  
 
Biochemical analysis 
 
Routine biochemistry analyses were conducted for urea, creatinine, and C-reactive 
protein (CRP). Levels of the latter > 5 mg/l were considered high. Parathyroid hormone 
(PTH) concentrations were measured on the Beckman Access® 2 immunoassay system 
(Beckman Coulter, High Wycombe, UK). Assays for osteoprotegerin (OPG), receptor 
activator of nuclear factor kappa B ligand (RANKL), bone alkaline phosphatase (BAP) 
were performed on the automated ELISA (enzyme linked immunosorbent assay) 
analyzer, Triturus® (Grifols, Cambridge, UK). Matrix Gla protein (MGP) was quantified 
using the BIOMEDICA GRUPEE kit (BI-20062). All analyses were performed in 
duplicate. 
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Isolation and culture of rat aortic smooth muscle cells  
 
Cells were isolated as previously described [6] using aortic explants obtained from male 
Wister rats and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with penicillin (100 U ml-1), streptomycin (100 µg ml-1) and either 10% foetal bovine or 
human serum.  
 
Induction of calcification in rat cultured aortic smooth muscle cells 
 
Cells in 96-well plates were allowed to grow to 60-70 % confluency over 48 hours 
before being incubated with 10% serum in the absence (Controls) and presence of a 
widely used standard calcification buffer consisting of 7mM calcium Chloride (CaCl2) 
plus 7mM β-glycerophosphate (β-GP) [7]. To ensure that any subsequent 
mineralisation was regulated and reflective of genuine calcification of cells rather than 
non-physiological spontaneous precipitation of excess calcium phosphate, parallel 
experiments were carried out where CaCl2 (7 mM) and β-GP (7 mM) were incubated 
either in empty wells or with cells fixed with 10% formaldehyde. All incubations were 
terminated after the designated time period which varied from 1 to 7 days. 
 
Determination of calcification and total cell protein content  
 
Cell monolayers were lysed with buffer consisting of 10 mM TRIS (pH 7.4) and 10 % 
sodium dodecyl sulphate. Calcification was determined using the DICA-500 Ca+2 assay 
Kit from Bioassay System (Universal Biologicals, UK), according to the manufacturer’s 
instructions. Total protein content was measured using the bicinchoninic acid (BCA) 
protein assay as described previously [8]. Once determined, calcium levels in lysates 
were normalised for total cell protein per well and the data presented as nmoles Ca
+2
 
protein mg-1. 
 
In parallel experiments, cells were viewed at 10x magnification using a Nikon confocal 
microscope under normal view to visualise plaques formed as a consequence of 
calcification. 
 
Cell Viability Assay 
 
Cell viability was determined under the different experimental conditions by assessing 
the metabolism of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
formazan as described previously [8].  
 
Statistical Analysis 
 
Statistical analysis was carried out using SPSS, version 17 and the data presented as 
the mean ± SD for normally distributed, and as median (interquartile range) if not 
normally distributed. For continuous variables the significance of differences between 
two groups was determined by student t test (for normally distributed data) and the 
Mann-Whitney U-tests (for non-normally distributed data). One Way Analysis of 
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Variance followed by Bonferroni post-hoc testing or the Kruskal-Wallis test was used to 
compare multiple groups as appropriate. The Chi-squared test was used to differentiate 
between the groups with respect to categorical data. Correlations utilised the Pearson 
and Spearman test as appropriate. For multivariate analysis, values of calcific potential 
were log-transformed. 
 
Materials 
 
Cell culture reagents and other general biochemical reagents including CaCl2 and β-GP 
were purchased from Sigma-Aldrich (London, UK). Penicillin and streptomycin was from 
Fisher Scientific (Loughborough, UK) and foetal bovine serum (FBS) from Gibco 
(Scotland, UK). The BCA protein quantification Kit was from Thermo Scientific (Hemel 
Hempstead, UK) and the DICA-500 Ca+2 assay Kit was from Universal Biologicals 
(Cambridge, UK). Reagents for OPG, RANKL, BAP were obtained from Oxford 
biosystems, Oxford, UK. 
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RESULTS 
 
Demographics and clinical factors  
 
All subjects were Caucasian. There were no significant differences in age or gender 
ratios across the groups. Systolic blood pressure (SBP) was significantly lower in the 5D 
group than in patients with advanced CKD, and diastolic blood pressure (DBP) was 
significantly lower in the 5D than in both pre-dialysis groups (Table 1). 
 
Baseline biochemistry and hematology  
 
CKD groups differed significantly from controls with respect to haemoglobin, serum 
albumin, cholesterol, phosphate, PTH, OPG, and RANKL levels and with respect to 
OPG/RANKL ratio (Table 1). Serum phosphate increased with advancing CKD while 
serum calcium was unchanged. Haemoglobin levels were higher in moderate CKD than 
in the 5D group. Serum albumin was higher in both moderate and advanced CKD groups 
than in 5D patients. Likewise the proportion with elevated CRP levels was greater in the 
5D group then in both other CKD groups. Bone alkaline phosphatase levels were similar 
in all CKD groups. Parathyroid hormone and OPG levels were significantly higher in 5D 
patients than both pre-dialysis groups, whilst RANKL levels and OPG/RANKL ratios did 
not differ significantly between CKD stages. Matrix Gla protein has so far been 
determined only in the 5D group in which levels were significantly lower than in controls 
(Table 1). 
 
Development of an in vitro model of calcification  
 
In order to be able to determine the effects of serum from human patients on the 
development of VC, an in vitro model of this process was initially established using rat 
cultured aortic smooth muscle cells (RASMCs) exposed to CaCl2 and β-GP as a 
phosphate source. Each compound was used at a concentration of 7mM and this was 
predetermined from pilot studies using 2mM to 20mM of either component. At 2mM 
there was little or no evidence of calcification, while at higher concentration (≥15mM) 
Ca+2 precipitated with β-GP in the medium (data not shown). A 7mM concentration of 
each combined was found to give consistent and optimum calcification. As shown in 
Figure 1A, incubation of cells for 5 days with complete culture medium supplemented 
with 10 % FBS resulted in marginal calcification. Inclusion of 7mM CaCl2 enhanced 
calcification while β-GP (7mM) was without significant effect. By comparison, inclusion 
of both together caused a marked increase in the calcification which was much greater 
than the additive effects.  
 
Photographs taken of cells following the different treatment conditions (Figure 1B) 
revealed a normal monolayer under control conditions with little evidence of calcification 
as indicated by the lack of calcific plaques. Incubations with CaCl2 at 7mM showed 
moderate plaque formation while cells incubated with β-GP exhibited less marked 
effects. Consistent with the calcification data (Figure 1A), co-incubations with CaCl2 and 
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β-GP (both at 7mM) caused marked calcific plaque formation throughout the monolayer 
(Figure 1B). 
 
In parallel studies, the time course of calcification was determined over 7 days. The 
data presented in Figure 1C show a time dependent increase which was evident after 
Day 3, reaching a peak at Day 5 but declining by Day 7. This trend was only evident 
when cells were incubated with CaCl2 together with β-GP. The basal levels of 
calcification seen with culture medium alone did not change significantly over time 
(Figure 1C). 
 
Assessment of cell viability using the MTT assay showed that survival was unaffected at 
days 1 to 5 but significantly reduced at day 7 as reflected by the marked inhibition of 
MTT metabolism to formazan (Figure 1D). This decrease in cell viability may account for 
the decreases in calcification observed at day 7 and as a result all subsequent 
experiments were carried out over a 5 day period.   
 
3.3. Effects of human serum on calcification of RASMCs 
 
Incubation of cells with serum from patients with CKD induced calcification of RASMCs 
outside the disease milieu. More importantly, there was a graded response in total 
cellular calcium content and deposition of calcium phosphate crystals. These changes 
which we have defined as the calcific potential of serum, correlated with the degree of 
renal impairment. This is clearly evident in Figure 2 which shows that serum from 5D 
patients had a greater calcific potential than serum obtained from stage 3 or stage 4/5. 
Control human serum did not cause any obvious calcification of cell monolayers and the 
total detected levels of calcium (50.8±9.3 ) were not significantly different to those in 
cells incubated with FBS (32.2±8.4 nmoles Ca
+2
 protein mg-1; p=0.30). These levels are 
consistent with other studies in smooth muscle cells [9, 10]. However the degree of 
calcification in our studies was less, perhaps due to the difference in the species and 
incubation period. 
 
In the whole group, the calcific potential of serum correlated positively with blood urea, 
serum creatinine, phosphate, OPG and PTH, and negatively with DBP, haemoglobin 
and albumin (Table 2). In stepwise multivariate analysis the significant predictors of log 
transformed calcific potential were serum creatinine (p<0.001), albumin (p=0.009) and 
OPG (p=0.010). These factors however only explain around 50% of the variation in 
calcific potential (r2=0.506). Other parameters including age, serum cholesterol, 
phosphate, PTH and high CRP were not significant in this model. The calcific potential 
of serum could therefore be influenced by other as yet unidentified factors.  
 
In view of the graded response reported above, we were interested in establishing 
whether the calcific potential of the stages 3, 4/5 or 5D sera could be enhanced under 
conditions that may be associated with calcification in vivo (such as the presence of 
high calcium and phosphate). We therefore investigated the effects of co-incubating 
RASMCs with serum samples and both CaCl2 (7mM) and β-GP (7mM). In these 
studies, the calcific potential of serum from stage 3 and 4/5 CKD groups was 
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significantly enhanced whilst no significant increment was apparent with control or 5D 
samples (Figure 3). Interestingly, within the latter (5D group) we observed that half the 
samples (referred to here as responders) did show an increase in calcification above 
that seen with serum alone when co-incubated with CaCl2 and β-GP while the other half 
(non-responders) did not (Figure 4). What was even more striking was that responders 
had significantly higher levels of MGP (p=0.003), high density lipoprotein (HDL; 
p=0.004) and RANKL (p=0.012) when compared to the non-responders. Serum 
phosphate was lower and serum albumin higher in the responders but this did not attain 
statistical significance. Other levels of other potential modulators of calcification in Table 
1 were not significantly different between the two groups.  
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DISCUSSION 
 
Although plasma constituents are believed to regulate vascular calcification, it is not 
entirely clear how the various molecules act, nor is the complex interplay amongst the 
key factors established. Furthermore, the critical role of each biomarker, in terms of 
which might be the most important molecule(s) remains unresolved. Of particular 
relevance to the current manuscript is the additional question about whether their 
presence in serum may be sufficient to regulate calcification outside of disease settings. 
If established, the latter may be of clinical significance in defining thresholds of calcific 
potential and predicting risks of calcification in vivo which might inform therapeutic 
strategies.    
 
With the exception of studies by Chen et al demonstrating that pooled uremic sera may 
accelerate calcification in bovine cultured vascular smooth muscle cells, there are no 
studies that have examined the direct calcific potential of non-pooled serum or its 
constituents in an in vitro setting [5]. More importantly, the key question of whether the 
calcific potential of serum is dependent on the degree of renal impairment has not been 
addressed. We have therefore correlated the degree of in vitro calcification with the 
severity of renal impairment in vivo and have looked at the association between several 
biomarkers and the degree of calcification induced in vitro.  
 
In developing our model, we examined the effects of Ca+2 alone, phosphate in the form 
of β-GP and a combination of both at pre-determined concentrations. The degree of 
calcification was less pronounced with CaCl2 and even less so with β-GP alone but 
clearly evident when both were used in combination. These results suggest that, on 
their own, neither CaCl2 nor β-GP may be sufficient to induce profound calcification, at 
least in vitro. That this contradicts other studies may be due to differences in the 
duration of experiments, which in ours were over a shorter period (5 days). Others were 
prolonged, obtaining calcification after incubations of between 20 to 30 days [5, 11]. It is 
therefore likely that when used individually, CaCl2 or phosphate may require a longer 
duration to cause calcification. The advantage of our model however is that calcification 
was significantly induced and evident within a period during which optimal cells 
confluency was maintained and viability was not compromised. Moreover, the process 
was time-dependent supporting the notion that it is regulated and not simply a 
consequence of aggregation of Ca+2 and phosphate to form crystals. One conclusion 
we have not been able to draw from our studies is whether the changes we observed 
involved a change in phenotype or indeed differentiation of the cells into bone-like 
structures and this remains to be established.  
 
The results obtained with the clinical samples confirm that serum from CKD settings 
can induce calcification of normal healthy smooth muscle cells in vitro. Moreover, we 
have provided the first demonstration of this effect being graded, correlating well with 
the severity of renal impairment in vivo. In the first instance, the 5D sera had the most 
striking calcific potential which was effectively 2-fold higher than the increases seen 
with the CKD3  or CKD 4/5 and at least 8-fold higher than the controls samples. With 
the limited sample size used in our studies, there was no notable difference in the 
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effects obtained with the CKD3 and the CKD4/5 sera but both were significantly higher 
than baseline values.  
 
The events and mechanisms underlying the effects described above have not yet been 
investigated. Studies aimed at addressing these are now planned and will include 
analysis of fetuin A and FGF-23 which are emerging as critical regulators of calcification 
[12]. In the interim we have analysed our samples for calcium and phosphate as well a 
number of other putative biomarkers of in vivo calcification and correlated these with the 
calcific potential of serum in our model.  
 
The first notable observation was that calcium was not significantly elevated above 
controls nor was it significantly different between the three CKD groups. Phosphate 
levels on the other hand increased relative to the degree of renal impairment and 
correlated positively with in vitro calcification. However, in our multivariate model 
phosphate was not independently associated with calcific potential, suggesting that it 
may not be critical in this process. This would be consistent with our earlier 
demonstration that phosphate, on its own, is not sufficient to induce calcification in vitro 
over periods not associated with detrimental changes in cell survival and viability. Moe 
et al have also indicated that serum factors other than phosphate may be required for 
inducing calcification in vitro [13]. These observations do not support other published 
literature [14-16].  
 
Blood urea, serum creatinine, PTH and OPG also increased in parallel with the severity 
of renal failure and correlated positively with calcific potential. Although serum 
creatinine was an independent predictor of calcific potential in our multivariate model it 
is only a marker of renal dysfunction. Parathyroid hormone on the other hand remains 
controversial, with some studies claiming elevated levels determine the severity and 
progression of VC [17] while others have suggested that it may inhibit calcification [18]. 
To further compound the controversy, other groups have failed to establish a link 
between PTH and VC in patients with CKD [19, 20]. There was also no independent 
association of PTH with calcific potential in our multivariate model suggesting that it is 
not directly involved in the process. Whilst OPG has been implicated as a key inhibitor 
of VC in animal models [21, 22], levels are reported to be elevated in serum from CKD 
patients on dialysis [23, 24] and have been strongly correlated with the severity of 
coronary calcification [11, 25]. We found OPG to be independently associated with 
calcific potential in multivariate modeling, supporting a role in vitro and in the genesis of 
VC in humans.  
 
Albumin decreased with advancing CKD and was negatively correlated with calcific 
potential with which it was independently associated in our multivariate analysis. This 
may still be a reflection of the severity of the degree of renal impairment but may also 
indicate a regulatory role in the pathogenesis of VC perhaps by inhibiting calcification 
through attenuation of seeding of calcium phosphate crystals [26]. C-reactive protein and 
cholesterol which may have roles in the development of in vivo calcification [27] were 
associated with serum calcific potential in univariate analyses of our data. We did not 
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however find evidence of independent association, but this does not preclude a role for 
inflammation or lipid abnormalities in the in vitro model.  
 
In parallel with establishing the direct effects of serum we also explored whether calcific 
potential could be enhanced by increasing calcium and phosphate concentrations in the 
incubation medium. Addition of CaCl2 and β-GP increased the calcific potential of the 
predialysis sera but did not alter that of the control or haemodialysis group significantly.  
The lack of enhancement of the calcific potential of 5D sera led us to examine individual 
samples more closely and this identified two distinct groups which we have referred to 
as responders and non-responders. The former showed decreased calcific potential 
when compared to the non-responders. However, the calcific potential of serum from 
responders could be enhanced by CaCl2 and β-GP which was not evident with serum 
from non-responders. Further analysis of the biochemical parameters revealed that 
non-responders had significantly lower levels of BAP, HDL, RANKL and MGP. 
Phosphate levels were higher and albumin levels lower in this group but not significantly 
so. It may be that in non-responders, the potential to calcify is maximal even before 
addition of extra calcium and phosphate. In contrast, in responders, perhaps associated 
with higher ambient levels of inhibitors (e.g. HDL, MGP, RANKL) and lower levels of 
promoters (ie high albumin and low phosphate), the potential to calcify is sub-maximal, 
and only fully expressed on addition of extra calcium and phosphate.  
 
In summary, we have developed a model of VC which we have exploited to 
demonstrate the calcific potential of serum and shown that this correlated with the 
degree of uraemia in patients. The model appears suitable for screening clinical 
samples and offers a reproducible but yet simple system that could be employed in 
predicting risks of calcification in vivo. Additionally, the model can now be utilised to 
identify critical biomarker surrogates and mechanisms responsible for the calcific 
potential of the serum. This may lead to the development of diagnostic tools and inform 
therapeutic strategies.  
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Table 1: Biochemical parameters of serum from controls and CKD subjects 
 
NS = non-significant, SBP = systolic blood pressure, DBP = diastolic blood pressure, 
eGFR (ml/min/1.73m2) = estimated glomerular filtration rate calculated using MDRD 4 
formula, CRP = C-reactive protein, BAP = bone specific alkaline phosphatase, PTH = 
parathyroid hormone, OPG = osteoprotegerin, RANKL = receptor activator of nuclear 
factor kappa B ligand, MGP = matrix Gla protein. Normally distributed parameters 
represented as mean ± standard deviation. Non-normally distributed parameters 
represented as median (minimum, maximum). *p < 0.05; **p < 0.01; †p < 0.001 denote 
significant difference from controls by ANOVA. 
 
Table 2: Correlation coefficients of serum calcific potential with biomarkers 
 
Serum PTH = serum parathyroid hormone, serum OPG = serum osteoprotegerin and 
eGFR (ml/min/1.73m2) = estimated glomerular filtration rate calculated using MDRD 4 
formula. Calcification potential values were correlated with particular biochemical 
variables using Pearson’s or Spearman correlation as appropriate.  
 
Figure 1: Induction of calcification and assay for cytotoxicity in RASMCs. 
 
Cells cultured to 60 % confluency were incubated for 5 days with either complete culture 
medium alone (Control; open bar), media containing 7mM CaCl2, 7mM β-GP (solid bars) 
or a combination of both (Panel A). In parallel studies cells were incubated with 7mM 
CaCl2 plus 7mM β-GP for different time points (Panel C). Calcification was quantified 
and normalised for total cell protein as described in the methods. The formation of 
calcific plaques was visualised under an inverted microscope at x40 magnification and 
the photograph (Panel B) is representative of at least 3 independent experiments. 
Changes in cell viability was determined as described in methods and represented in 
Panel D. The data is the mean ± SEM from 3 experiments with 5 replicates in each. • 
denotes p<0.05, •• denotes p<0.01, ••• denotes p<0.001 when compared to controls (C).  
 
Figure 2: Calcification of RASMC by serum from patients with CKD. 
 
Cells cultured to 60 % confluency were incubated for 5 days with complete culture 
medium and 10% serum from controls (open bar) or from subjects with CKD3, CKD4/5 
or on haemodialysis (solid bars). Calcification was quantified and normalised for total 
cell protein as described in the methods. The data represents the mean ± SEM from 3 
experiments with 5 replicates in each. • denotes p<0.05, •• denotes p<0.01, ••• denotes 
p<0.001 statistical significance. 
 
Figure 3: Effects of CaCl2 and β-GP on serum-induced calcification. 
 
Cells cultured to 60 % confluency were incubated for 5 days with complete culture 
medium containing 10% control (open bar) or  CKD Sera in the absence (solid black 
bars) and presence of CaCl2 (7mM) and β-GP (7mM) (hatched bars). Calcification was 
quantified and normalised for total cell protein as described in the methods. The data 
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represents the mean ± SEM from 3 experiments with 5 replicates in each. •• denotes 
p<0.01 statistical significance.  
 
 
 
Figure 4: Effects of CaCl2 and β-GP on serum-induced calcification in responders 
and non-responders. 
 
Cells cultured to 60 % confluency were incubated with (hatched bars) or without CaCl2 
(7mM) and β-GP (7mM) (solid bars) for 5 days in complete culture medium containing 
10% Serum from subjects on haemodialysis. Calcification was quantified and 
normalised for total cell protein as described in the methods. The data represents the 
mean ± SEM from 3 experiments with 5 replicates in each.  • denotes p<0.05 statistical 
significance.
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Table 1: Biochemical parameters of serum from controls and CKD subjects 
 
Variables  Groups 
 Control Moderate  
CKD 
Advanced 
CKD 
Haemodialysis M v A M v HD A v HD 
 (C) (M) (A) (HD) p-value p-value p-value 
Number 20 21 18 30 NS NS NS 
Age (yrs) 63 ± 6.2 64 ± 9.8 66 ± 17 64 ± 14
 
NS NS NS 
Gender (M:F) 12/8 15/6 10/8 22/10 NS NS NS 
SBP (mmHg) 150 ± 24 145 ± 13 152 ± 27 134 ± 17 NS NS 0.026 
DBP (mmHg) 87 ± 9 85 ± 12 89 ± 11 73 ± 11
†
 NS 0.002 <0.001 
Creatinine (umol/l) 72 ± 17 150 ± 29 291 ± 80
† 
751 ± 235
†
 0.017 <0.001 <0.001 
eGFR (MDRD 4) 94 ± 24 42 ± 8
†
 19 ± 5
†
 NA <0.001 NA NA 
Urea (mmol/l) 5.2 ± 1.2 10.3 ± 2.4** 20.3 ± 6
†
 20.7 ± 6
†
 <0.001 <0.001 NS 
Haemoglobin (g/dl) 14.0 ± 1.0 12.7 ± 2.4 11.2 ± 2 11.1 ± 1.1** NS 0.010 NS 
High CRP  % 15 33 22 50* NS NS 0.016 
Calcium(mmol/l) 2.49 ± 0.13 2.41 ± 0.12 2.37 ± 0.1 2.37 ± 0.2 NS NS NS 
Cholesterol (mmol/l) 5.8 ± 1.0 4.8 ± 1.1* 4.6 ± 1.0** 4.1 ± 1.2
†
 NS NS NS 
HDL  Cholesterol (mmol/l) 1.5 ± 0.3 1.2 ± 0.3 1.4 ± 0.4 1.3 ± 0.6 NS NS NS 
Phosphate (mmol/l) 1.02 ± 0.15 1.11 ± 0.24 1.34 ± 0.26* 1.66 ± 0.47
† 
NS <0.001 0.010 
Albumin (g/l) 45.4 ± 2.5 41.1 ± 4.7** 41.8 ± 4.8* 37.4 ± 2.9** NS 0.005 0.001 
BAP (IU/l) - 26.2 ± 6.4 28.6 ± 6.8 24.1 ± 6.7 NS NS NS 
PTH (pmol/l) 4.0 (2.3, 6.1) 3.0 (1.2, 22.9) 5.6 (1.9, 25.6) 17.8 (1.0, 43.7)
†
 NS <0.001 <0.001 
OPG (pmol/l) 4.0 ± 1.5 5.4 ± 1.7 5. 8 ± 2.2
 
9.8 ± 3.7
†
 NS <0.001 <0.001 
RANKL (pmol/l) 0.0 (0, 0.44) 0.05 (0, 0.47)
†
 0 (0, 0.42)
†
 0.02 (0, 0.37)
†
 NS NS NS 
OPG RANKL Ratio 75.7 (7.4, 291) 12.7 (5.3,41.2)
†
 15.9 (6.1, 71.5)
†
 16.3 (7.3, 35.4)
†
 NS NS NS 
MGP (ng/ml) 15.4 ± 1.4 - - 1.94 ± 0.8 - - - 
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Table 2: Correlation coefficients of serum calcific potential with biomarkers  
 
Variables Calcific potential of 
serum 
Coefficient p-value 
Serum Creatinine 0.725 <0.001 
Blood urea 0.600 <0.001 
Serum PTH 0.455 <0.001 
Serum OPG 0.419 <0.001 
Serum phosphate 0.539 <0.001 
MDRD eGFR -0.551 <0.001 
Diastolic blood 
pressure 
-0.411 
<0.001 
Haemoglobin -0.382 <0.001 
Serum albumin -0.451 <0.001 
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Figure 2 
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Figure 3 
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Figure 4 
Non-Responders Responders
0
100
200
300
400
500 .
C
a
+
2
 n
m
o
le
s
 p
ro
te
in
 m
g
-1
   
